Pomerantz LLP is investigating Corning Incorporated and some of its executives for potential securities fraud following Corning's announcement of a $2 billion at-the-market equity offering with Goldman Sachs. The announcement led to a 13.7% drop in Corning's stock price, raising concerns among investors. The investigation aims to determine if Corning engaged in unlawful business practices. Investors affected by the price drop are encouraged to contact Pomerantz LLP for potential class action participation.
The story concerns Corning Incorporated and an investigation into its recent equity offering. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 18, 2026 06:21 WIB: of 150 priced Technology-sector US stocks tradable on Pluang, 109 rose and 38 fell today. Notable movers include UMC at USD 24.40 with a 1-day change of +8.30% and Pluang order activity of 92% Sell / 8% Buy, INTC at USD 109.24 with +8.10% change and 69% Sell / 31% Buy activity, and HPE at USD 61.14 with +8.08% change and 42% Sell / 58% Buy activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
